<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00881218</url>
  </required_header>
  <id_info>
    <org_study_id>REGADENOSON.MRI.WUSTL</org_study_id>
    <nct_id>NCT00881218</nct_id>
  </id_info>
  <brief_title>Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson</brief_title>
  <official_title>Feasibility of Detecting Myocardial Ischemia by First-pass Contrast MRI Using Regadenoson</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to determine whether the drug regadenoson can be used during magnetic
      resonance imaging to assess regions of poor blood flow to the heart.

      The hypothesis of this study is that a single injection of regadenoson could be used instead
      of a standard adenosine infusion to produce coronary vasodilatation and demonstrate
      myocardial ischemia during first-pass perfusion cardiac MRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study that proposes to assess the feasibility of using regadenoson (Lexiscan,
      Astellas), a recently FDA approved A2A receptor agonist, as the stress perfusion agent in
      cardiac MRI perfusion examinations. While regadenoson has been approved by the FDA, it has
      not been approved for the specific indications of use 1) during the simultaneous intravenous
      administration of a gadolinium-based contrast agent, or 2) during magnetic resonance imaging
      (MRI).

      Because this agent can be given intravenously in a single 400 microgram bolus, rather than in
      an infusion, this agent may be easier to administer than adenosine during an MRI examination.

      The objectives for this pilot study are: 1) To demonstrate the feasibility of using
      regadenoson during cardiac perfusion MRI to visualize known regions of myocardial ischemia as
      demonstrated on SPECT-MPI and 2) To describe a cardiac perfusion MRI protocol using
      regadenoson that would have the potential to be used clinically.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of use of regadenoson during cardiac perfusion MRI to visualize regions of myocardial ischemia as demonstrated on SPECT-MPI.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Regadenoson CMR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Images in the cardiac short axis will be obtained using a gradient recalled echo sequence, TR 2.3 msec/TE 1.1 msec, 80*256 matrix, slice thickness 10 mm. Images will be obtained during power injection of 0.075 mmol/Kg of a conventional gadolinium based MR contrast agent at a rate of 5 mL/sec followed by a 15 mL saline flush into an antecubital vein. Perfusion imaging will be performed at stress and rest. Stress: Regadenoson 400 mcg will be administered IV bolus via an antecubital cannula. Immediately after injection, MR scanning will begin and contrast will be given. Rest: After 10 minutes, rest imaging will be performed identically, but without regadenoson injection. To identify late enhancement of myocardial tissue inversion recovery prepared images will be obtained.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson</intervention_name>
    <description>Regadenoson 400 micrograms will be administered IV bolus via an antecubital cannula.</description>
    <arm_group_label>Regadenoson CMR</arm_group_label>
    <other_name>Lexiscan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  reversible perfusion abnormalities on a clinically ordered rest/adenosine dual-isotope
             SPECT-MPI in at least 2 contiguous myocardial segments (per 17-segment model)

        Exclusion Criteria:

          -  myocardial infarction, myocardial revascularization procedure or progression in angina
             occuring after the SPECT-MPI examination

          -  pregnancy

          -  gadolinium-based MR contrast allergy

          -  glomerular filtration rate (GFR) &gt; 60 mL/min/1.73 m2

          -  contraindications to MR imaging (pacemaker, brain aneurysm clips, schrapnel, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela K. Woodard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Aljaroudi W, Hermann D, Hage F, Heo J, Iskandrian AE. Safety of regadenoson in patients with end-stage renal disease. Am J Cardiol. 2010 Jan 1;105(1):133-5. doi: 10.1016/j.amjcard.2009.08.663. Epub 2009 Nov 18.</citation>
    <PMID>20102905</PMID>
  </reference>
  <reference>
    <citation>Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, Lieu H, Mahmarian JJ, Olmsted A, Underwood SR, Vitola J, Wang W; ADVANCE MPI Investigators. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 2007 Sep-Oct;14(5):645-58.</citation>
    <PMID>17826318</PMID>
  </reference>
  <reference>
    <citation>Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE; ADVANCE-MPI Trial Investigators. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging. 2008 May;1(3):307-16. doi: 10.1016/j.jcmg.2008.02.003.</citation>
    <PMID>19356442</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2009</study_first_submitted>
  <study_first_submitted_qc>April 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2009</study_first_posted>
  <last_update_submitted>April 8, 2012</last_update_submitted>
  <last_update_submitted_qc>April 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Pamela Woodard, MD</investigator_full_name>
    <investigator_title>M.D., FACR, FAHA, FCCP</investigator_title>
  </responsible_party>
  <keyword>myocardial ischemia, perfusion imaging, cardiac MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Regadenoson</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

